Literature DB >> 1582883

HTLV-I uveitis: a distinct clinical entity caused by HTLV-I.

M Mochizuki1, T Watanabe, K Yamaguchi, K Takatsuki, K Yoshimura, M Shirao, S Nakashima, S Mori, S Araki, N Miyata.   

Abstract

Seroepidemiological, clinical and virological studies were carried out in an HTLV-I endemic area to find out if HTLV-I caused an intraocular inflammatory disorder, uveitis. The seroprevalence in patients with uveitis without defined etiologies (62/175, 35.4%) was significantly higher than that in patients with non-uveitic ocular diseases (42/261, 16.1%) or in patients with uveitis with defined etiologies (8/78, 10.3%). Moreover, the seroprevalence in young adults (20-49 years) with uveitis without defined etiologies was 30/67 (44.8%), whereas it was only 10/107 (9.3%) in the other two groups. The uveitis in HTLV-I carriers was characterized clinically by a moderate inflammation of the vitreous body accompanied by a mild iritis and retinal vasculitis. The proviral DNA of HTLV-I was detected by polymerase chain reaction from the inflammatory cells in the anterior chamber in 9 out of 9 seropositive patients with the uveitis, but not in any of the tested patients with other types of uveitis. These data, thus, indicate that HTLV-I causes a specific type of intraocular inflammation, uveitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1582883      PMCID: PMC5918816          DOI: 10.1111/j.1349-7006.1992.tb00092.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  7 in total

1.  Noninfectious anterior uveitis in patients infected with human T-lymphotropic virus type I.

Authors:  K Nakao; N Ohba; M Matsumoto
Journal:  Jpn J Ophthalmol       Date:  1989       Impact factor: 2.447

2.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

3.  [Anti-human T-cell leukemia virus antibody distribution in Miyazaki Prefecture].

Authors:  N Tachibana; A Okayama; E Kusune; T Yokota; E Shishime; K Tsuda; H Matano
Journal:  Kansenshogaku Zasshi       Date:  1984-08

4.  Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.

Authors:  A Gessain; F Barin; J C Vernant; O Gout; L Maurs; A Calender; G de Thé
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

5.  Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease.

Authors:  M Yoshida; M Seiki; K Yamaguchi; K Takatsuki
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

6.  The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group.

Authors:  K Tajima
Journal:  Int J Cancer       Date:  1990-02-15       Impact factor: 7.396

7.  Seroprevalence of antibodies to HTLV-I in patients with ocular disorders.

Authors:  K Nakao; M Matsumoto; N Ohba
Journal:  Br J Ophthalmol       Date:  1991-02       Impact factor: 4.638

  7 in total
  75 in total

1.  Clinical significance of serum soluble IL-2R levels in patients with adult T cell leukaemia (ATL) and HTLV-1 carriers.

Authors:  K Araki; K Harada; K Nakamoto; M Shiroma; T Miyakuni
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

Review 2.  HTLV-1 infections.

Authors:  C R Bangham
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

3.  Human T-lymphotropic virus type I or II (HTLV-I/II) associated with recurrent longitudinally extensive transverse myelitis (LETM): two case reports.

Authors:  Silvia R Delgado; William A Sheremata; Andrew D Brown; Micheline McCarthy
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

4.  A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network.

Authors:  Pia Rücker; Anselm H C Horn; Heike Meiselbach; Heinrich Sticht
Journal:  J Mol Model       Date:  2011-01-29       Impact factor: 1.810

Review 5.  Polymerase chain reaction in the diagnosis of uveitis.

Authors:  Chi-Chao Chan; DeFen Shen; Jingsheng Tuo
Journal:  Int Ophthalmol Clin       Date:  2005

Review 6.  Implication of the HTLV-I bZIP factor gene in the leukemogenesis of adult T-cell leukemia.

Authors:  Yorifumi Satou; Masao Matsuoka
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

7.  The relationship between HTLV-I-infected cell lines and uveitis.

Authors:  A Fukushima; H Ueno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-04       Impact factor: 3.117

8.  Increased number of circulating HTLV-1 infected cells in peripheral blood mononuclear cells of HTLV-1 uveitis patients: a quantitative polymerase chain reaction study.

Authors:  A Ono; M Mochizuki; K Yamaguchi; N Miyata; T Watanabe
Journal:  Br J Ophthalmol       Date:  1995-03       Impact factor: 4.638

9.  Provirus expansion and deregulation of apoptosis-related genes in the spinal cord of a rat model for human T-lymphocyte virus type I-associated myeloneuropathy.

Authors:  Utano Tomaru; Hitoshi Ikeda; Xiuyun Jiang; Osamu Ohya; Takashi Yoshiki
Journal:  J Neurovirol       Date:  2003-10       Impact factor: 2.643

10.  Clinical features of HTLV-I associated uveitis.

Authors:  K Nakao; N Ohba
Journal:  Br J Ophthalmol       Date:  1993-05       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.